Bionaturis Group has released FY2015 audited results showing a continuous growth in many of its main performance indicators at organic level. Thus, the recurring business coming from the CRO and consumer products divisions has grown 21.7% YOY, meaning a CAGR of 24.1% on net sales for the whole group between 2012-15. Regarding the human and animal health division -which business model requires a more focused analysis on the richness and quality of the pipeline- the Group announced the addition of up to six new programs, five of which are targeted specifically to highly lucrative niche markets within animal health, positioning the group as a partner of choice for cutting-edge developments in this sector.

From the angle of an effective presence in other international markets the Group signed an outstanding agreement with the Administrative Committee of the high technology Industrial development zone of Changshu City (Jiangsu, China), which shall support the start up phase of the subsidiary BNT China Biosciences. Also during 2015 the subsidiary BBD Biophenix USA was created, generating an immediate effect on the increase of contracts with U.S. entities, such as the one signed with the NIH (National Institute of Health), a leading global institution in the health sector.

For further details, click here